• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血清叶酸受体α（sFR）在卵巢癌诊断和监测中的应用。

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance.

机构信息

Department of Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan.

Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan.

出版信息

Cancer Med. 2019 Mar;8(3):920-927. doi: 10.1002/cam4.1944. Epub 2019 Feb 13.

DOI:10.1002/cam4.1944
PMID:30761774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6434204/
Abstract

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.

摘要

新颖性和影响声明

我们的研究结果表明，可溶性叶酸受体（sFR）可用于卵巢癌患者的初始诊断和监测。我们的队列是迄今为止分析的 sFR 最大的比较组之一。我们使用健康志愿者定义了 sFR 的背景水平。这也是第一项前瞻性随访监测患者的研究，旨在同时识别肿瘤标志物 CA-125 和 sFR 的差异变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03e3/6434204/09fb082f5927/CAM4-8-920-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03e3/6434204/9981142385b4/CAM4-8-920-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03e3/6434204/09fb082f5927/CAM4-8-920-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03e3/6434204/9981142385b4/CAM4-8-920-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03e3/6434204/09fb082f5927/CAM4-8-920-g002.jpg

相似文献

1
Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance.血清叶酸受体α（sFR）在卵巢癌诊断和监测中的应用。
Cancer Med. 2019 Mar;8(3):920-927. doi: 10.1002/cam4.1944. Epub 2019 Feb 13.
2
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.一种多重生物标志物检测方法提高了 HE4 和 CA125 在卵巢肿瘤患者中的诊断性能。
PLoS One. 2020 Oct 19;15(10):e0240418. doi: 10.1371/journal.pone.0240418. eCollection 2020.
3
Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.CA125 和 HE4 对卵巢癌患者的诊断准确性及混杂因素对其血清水平的影响。
Curr Probl Cancer. 2019 Oct;43(5):450-460. doi: 10.1016/j.currproblcancer.2018.12.004. Epub 2019 Jan 16.
4
Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.血清叶酸受体α作为卵巢癌的生物标志物：对诊断、预后及预测其局部肿瘤表达的意义
Int J Cancer. 2016 Apr 15;138(8):1994-2002. doi: 10.1002/ijc.29937. Epub 2015 Dec 15.
5
[Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].[肿瘤标志物、评分（临床和生物学）算法在疑似上皮性卵巢癌的卵巢肿块诊断及预后评估中的价值：本文依据由FRANCOGYN、CNGOF、SFOG、GINECO - ARCAGY在CNGOF的支持下制定并经法国国家癌症研究所（INCa）认可的法国肿瘤学指南“上皮性卵巢癌患者的初始管理”起草]
Gynecol Obstet Fertil Senol. 2019 Feb;47(2):134-154. doi: 10.1016/j.gofs.2018.12.013. Epub 2019 Feb 5.
6
Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.血清人附睾蛋白 4 和癌抗原 125 在鉴别Ⅰ型和Ⅱ型上皮性卵巢癌中的意义。
Int J Gynecol Cancer. 2018 Jul;28(6):1058-1065. doi: 10.1097/IGC.0000000000001277.
7
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.用于检测卵巢癌的新型生物标志物组合的验证
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.
8
Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.联合 CA125 检测评估术前细胞角蛋白 19 片段 21-1 对上皮性卵巢癌的诊断和预后价值。
J Ovarian Res. 2019 Nov 25;12(1):114. doi: 10.1186/s13048-019-0587-0.
9
Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.卵巢癌的潜在风险因素及 CA125 标志物用于监测和诊断的分析。
Mol Biol Rep. 2019 Jun;46(3):3325-3332. doi: 10.1007/s11033-019-04794-8. Epub 2019 Apr 20.
10
Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer.术前血清 CA125、腹膜癌指数和术中绘图评分预测原发性上皮性卵巢癌的手术结果。
Int J Gynecol Cancer. 2020 Jan;30(1):62-66. doi: 10.1136/ijgc-2019-000778. Epub 2019 Nov 19.

引用本文的文献

1
Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.黏蛋白在用于卵巢癌治疗的抗体药物偶联物中的新兴作用。
J Ovarian Res. 2024 Aug 8;17(1):161. doi: 10.1186/s13048-024-01485-2.
2
Impedimetric Detection of Cancer Markers Based on Nanofiber Copolymers.基于纳米纤维共聚物的癌症标志物的阻抗检测。
Biosensors (Basel). 2024 Jan 31;14(2):77. doi: 10.3390/bios14020077.
3
Therapeutic strategies targeting folate receptor α for ovarian cancer.针对叶酸受体α的卵巢癌治疗策略。

本文引用的文献

1
Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer.副肿瘤抗原作为卵巢癌早期诊断的生物标志物
Gynecol Oncol Rep. 2017 Jun 15;21:37-44. doi: 10.1016/j.gore.2017.06.006. eCollection 2017 Aug.
2
Cancer cells exhibit clonal diversity in phenotypic plasticity.癌细胞在表型可塑性方面表现出克隆多样性。
Open Biol. 2017 Feb;7(2). doi: 10.1098/rsob.160283.
3
Cancer Statistics, 2017.《2017 年癌症统计》
Front Immunol. 2023 Aug 30;14:1254532. doi: 10.3389/fimmu.2023.1254532. eCollection 2023.
4
VCAM-1 complements CA-125 in detecting recurrent ovarian cancer.血管细胞黏附分子-1（VCAM-1）在检测复发性卵巢癌方面可辅助癌抗原125（CA-125）。
Clin Proteomics. 2023 Jun 25;20(1):25. doi: 10.1186/s12014-023-09414-z.
5
Role of biomarkers for early detection of ovarian cancer recurrence.生物标志物在卵巢癌复发早期检测中的作用。
Gland Surg. 2020 Aug;9(4):1102-1111. doi: 10.21037/gs-20-544.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.卵巢恶性肿瘤风险算法联合CA125和HE4对卵巢癌的诊断效能：一项Meta分析
Int J Gynecol Cancer. 2016 Nov;26(9):1586-1593. doi: 10.1097/IGC.0000000000000804.
5
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.用于检测卵巢癌的新型生物标志物组合的验证
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40. doi: 10.1158/1055-9965.EPI-15-1299. Epub 2016 Jul 22.
6
Current clinical application of serum biomarkers to detect ovarian cancer.血清生物标志物在卵巢癌检测中的当前临床应用。
Prz Menopauzalny. 2015 Dec;14(4):254-9. doi: 10.5114/pm.2015.55887. Epub 2015 Nov 27.
7
Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.血清叶酸受体α作为卵巢癌的生物标志物：对诊断、预后及预测其局部肿瘤表达的意义
Int J Cancer. 2016 Apr 15;138(8):1994-2002. doi: 10.1002/ijc.29937. Epub 2015 Dec 15.
8
The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics.基于病理特征将上皮性卵巢癌分为 I 型和 II 型肿瘤的预后价值。
Gynecol Oncol. 2015 Feb;136(2):205-11. doi: 10.1016/j.ygyno.2014.12.029. Epub 2014 Dec 27.
9
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.FOLR1表达与卵巢癌生存率之间时间依赖性关联的证据：对临床检测的意义。一项卵巢肿瘤组织分析联盟研究。
Br J Cancer. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30.
10
Ovarian cancer: diagnostic, biological and prognostic aspects.卵巢癌：诊断、生物学及预后方面
Womens Health (Lond). 2014 Sep;10(5):519-33. doi: 10.2217/whe.14.37.